Clinical trial · Interventional
C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT
C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment
NCT01691300CI-TRIAL-00019781ACTMMcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ACT PET/CT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ACT PET/CT
- description
- Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
- interventionNames
- Other: ACT PET/CT
Primary outcomes (1)
- measure
- Pretreatment lesion detection
- timeFrame
- Within 2 weeks before initiation of therapy
- description
- Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI
Secondary outcomes (2)
- measure
- Post-induction response assessment
- timeFrame
- Approximately 4 months after initiation of therapy depending on the regimen
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * at least 20 years of age * previously untreated * complete pre-treatment clinical staging including bone marrow examination * written informed consent to participate in the study Exclusion Criteria: * concurrent active malignant tumor(s) * pregnant or breast feeding women * non-compliant to PET/CT or to MRI * marked renal impairment (contraindicated for contrast-enhanced MRI)
References
Publications (0)
Data not yet available
No reference posted for this study.